WCG Publishes Report Providing Assessment of Motivators Across All Clinical Research Stakeholders

News provided by

Jul 12, 2023, 10:36 ET

PRINCETON, N.J., July 12, 2023 /PRNewswire/ -- WCG, one of the world's leading providers of solutions that measurably improve the quality and efficiency of clinical research, released its 2023 Avoca State of the Industry Report. The report provides a 360-degree review of what motivates or deters potential volunteers from participating in clinical trials, and what steps can be taken to encourage more participation, particularly among underrepresented groups.

The survey, conducted between December 2022 and March 2023, recruited respondents from stakeholders across the clinical trial continuum – sponsors, providers, site staff, and patients – to identify opportunities to improve both the participant and site experience. Findings demonstrate the ability to develop a clinical trial experience that is more "personal" will increase motivation to participate. The report includes actionable findings from multiple points of view, as well as a detailed sample composition and analytics by audience.

"For more than 20 years, Avoca has surveyed industry stakeholders to gain an understanding of key trends affecting outsourced clinical development," explains Christine Albano, general manager, WCG Benchmarking & Analytics. "This latest research included a broadened outreach to collect more diverse perspectives, focusing on the imperative of patient centricity and the need for expanding clinical trial participation."

The full 2023 Avoca State of the Industry Report contains high-level findings and implications for sponsors, providers, site staff, and patients, and can be accessed for free on Avoca's website.

About Avoca

Avoca, a WCG company, has been dedicated to improving quality and compliance in the clinical trial execution process. Integrating deep subject matter expertise with industry-leading approaches and technology, we tailor solutions that help companies build industry-leading quality management, inspection readiness, and effective oversight systems into existing processes. Our mission is to have a positive impact on all clinical trials by helping clinical research companies increase quality, ensure compliance, and improve efficiency so that medicines can reach patients faster. Avoca joined the WCG family of companies in April 2021. For more information, visit www.theavocagroup.com.

About WCG

WCG is a global leader of solutions that measurably improve and accelerate clinical research. Biopharmaceutical and medical device companies, contract research organizations (CROs), research institutions, and sites partner with us for our unmatched expertise, data intelligence, and purpose-built technology to make informed decisions and optimize study outcomes, while maintaining the highest standards of human participant protection. WCG raises the bar by pioneering new concepts, reimagining processes, fostering compliance and safety, and empowering those who perform clinical trials to accelerate the delivery of medical therapies and devices that improve lives. For more information, please visit wcgclinical.com or follow us on LinkedIn or Twitter @WCGClinical.

SOURCE WCG